Ahead of FDA decision, Alnylam faces the big question: Can it make money?

Despite pioneering RNAi drug development and getting four therapies approved, Alnylam still isn’t profitable. That may change as soon as next year. The FDA is expected to decide by Sunday whether to approve Alnylam's treatment ...